Song Zichen, Chen Hongguang, Xu Wenfei, Zong Xiaoye, Wang Xiaoyu, Ji Yuting, Gong Jiameng, Pang Mimi, Fung Shan-Yu, Yang Hong, Yu Yonghao
Department of Anesthesia, Tianjin Institute of Anesthesiology, Tianjin Medical University General Hospital, NO. 154 Anshan Road, Tianjin 300052, China.
Department of Pharmacology and Tianjin Key Laboratory of Inflammation Biology, The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, No. 22 Qixiangtai Road, Heping District, Tianjin 300070, China.
Mater Today Bio. 2025 Mar 27;32:101704. doi: 10.1016/j.mtbio.2025.101704. eCollection 2025 Jun.
Sepsis-induced systemic inflammatory responses can often lead to brain dysfunction with impaired cognitive function and mobility, known as sepsis-associated encephalopathy (SAE). Currently, there are no effective pharmacological therapeutics to treat SAE. Herein, we demonstrated the hexapeptide functionalized gold nanoparticles P12 that reduced SAE in septic mice with a dual mechanism to down-regulate systemic inflammation. We found that intraperitoneally administered P12 could target macrophages and regulate their inflammatory responses to decrease systemic inflammation and improve mice's cognitive function and mobility with SAE. Depleting peritoneal macrophages diminished the neuroprotective effects of P12 in SAE mice, suggesting macrophages as the effector cells for the neuroprotection by P12. In addition, the proteomic analysis revealed that P12 was capable of sequestering specific circulating inflammatory proteins in the blood of septic mice by forming a protein corona, contributing to the suppression of systemic inflammation. We also found that the local administration of P12 directly to the brain parenchyma effectively inhibited microglia activation and neuroinflammation in mice with SAE. This study provides an insightful understanding of the function and mechanisms of action of P12 in regulating sepsis-associated systemic inflammation and presents a new drug-free nanotherapeutic approach to treat SAE.
脓毒症诱导的全身炎症反应常常会导致脑功能障碍,伴有认知功能和运动能力受损,即脓毒症相关性脑病(SAE)。目前,尚无有效的药物疗法来治疗SAE。在此,我们展示了六肽功能化金纳米颗粒P12,其通过下调全身炎症的双重机制减轻了脓毒症小鼠的SAE。我们发现腹腔注射P12可以靶向巨噬细胞并调节其炎症反应,以减轻全身炎症,并改善患有SAE的小鼠的认知功能和运动能力。清除腹腔巨噬细胞会减弱P12对SAE小鼠的神经保护作用,这表明巨噬细胞是P12发挥神经保护作用的效应细胞。此外,蛋白质组学分析显示,P12能够通过形成蛋白冠在脓毒症小鼠血液中隔离特定的循环炎症蛋白,从而有助于抑制全身炎症。我们还发现,将P12直接局部给药至脑实质可有效抑制SAE小鼠的小胶质细胞活化和神经炎症。本研究为P12在调节脓毒症相关全身炎症中的功能和作用机制提供了深刻见解,并提出了一种新的无药纳米治疗方法来治疗SAE。
J Nanobiotechnology. 2021-2-19
J Neuroinflammation. 2024-1-30
Nat Rev Immunol. 2022-7
J Nanobiotechnology. 2021-2-19
ACS Appl Mater Interfaces. 2020-1-6